PPARA and cholangiocarcinoma: A phase I, open-label, dose-escalation study (NCT03829436) has been conducted to test the clinical activity of TPST-1120, a first-in-class oral inhibitor of PPARα, in patients with advanced renal cell carcinoma (RCC) and CCA.